1999 Abstract: 3486 THERAPEUTIC EFFECT OF ENDOSCOPIC MUCOSAL RESECTION USING O-RING
Abstracts 1999 Digestive Disease Week
# 3486
THERAPEUTIC EFFECT OF ENDOSCOPIC MUCOSAL RESECTION USING O-RING
Jun Myung Kim, Dong Ki Lee, Soon Koo Baik, Sang Ok Kwon, Wonju Med Coll, Wonju South Korea
(Aim) Endoscopic mucosal resection(EMR) has been widely used as a noninvasive therapeutic method in precancerous lesions, old age patients, high-risk operative group and selective early gastric cancer (EGC). Therefore, this study has been focused on evaluating the therapeutic effect of EMR by using o-ring and comparing survival rates of the patients wih EGC who had EMR with those who had radical gastrectomy. Seventy-seven patients (3cases with submucosal tumors, 47 with adenocarcinoma, 7 with severe dysplasia & 20 with EGC) whose postoperative follow-up observation for more than 6 months was possible and 35 EGC patients who had radical gastrectomy have been selected from February, 1994 to February, 1998. 1> The mean age of the patients who had EMR was 59.1years old and those with radical gastrectomy were 58.1years old. 2> The sizes of the lesions of the patients with EMR were as follows; 16 cases with the size less than 5 mm, 31 cases with 6 to 10 mm, 24 cases with 11 to 20 mm and 6case with the size more than 20 mm. 3> Primary complete resection rate was as follows; 100%(3/3cases) in submucosal tumor, 91.5%(43/47) in adenocarcinoma, 71.4%(5/7) in dysplasia and 65%(13/20) in EGC. The final complete resection rate was as follows; 95.7%(45/47) in adenocarcinoma, 71.4%(5/7) in dysplasia and 85%(17/20) in EGC. 4> The average follow-up period of time of the 17 cases of EMR was 31.5 months(6-54) and all the patients survived without recurrence of cancer except one case in which the patient died of cardiac disease. The mean follow-up period of time of 35 radical gastrectomy cases was 23.3 months(6-54)and so far, there has been no recurrence and the patients are still being observed. EMR using o-ring is a safe and non-invasive therapeutic method that can replace radical gastrectomy in precancerous lesions and selective EGC.